Q2 EPS Estimates for Veeva Systems Lifted by Zacks Research

Veeva Systems Inc. (NYSE:VEEV) – Equities researchers at Zacks Research lifted their Q2 2026 EPS estimates for shares of Veeva Systems in a research note issued on Wednesday, March 26th. Zacks Research analyst R. Department now forecasts that the technology company will earn $1.22 per share for the quarter, up from their prior forecast of $1.14. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ Q3 2026 earnings at $1.33 EPS, Q4 2026 earnings at $1.31 EPS, Q1 2027 earnings at $1.32 EPS and Q2 2027 earnings at $1.35 EPS.

Other equities research analysts also recently issued reports about the company. Royal Bank of Canada upped their target price on Veeva Systems from $275.00 to $285.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Stephens restated an “overweight” rating and issued a $280.00 price objective on shares of Veeva Systems in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $270.00 target price on shares of Veeva Systems in a report on Thursday, March 6th. Wells Fargo & Company upped their price target on shares of Veeva Systems from $275.00 to $285.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Finally, Barclays lifted their price objective on shares of Veeva Systems from $260.00 to $275.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.52.

Veeva Systems Trading Up 0.8 %

VEEV stock opened at $237.52 on Friday. The firm’s 50-day moving average is $231.27 and its two-hundred day moving average is $222.79. The company has a market capitalization of $38.56 billion, a price-to-earnings ratio of 58.65, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. Veeva Systems has a 52 week low of $170.25 and a 52 week high of $258.93.

Institutional Investors Weigh In On Veeva Systems

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VEEV. Principal Financial Group Inc. raised its holdings in shares of Veeva Systems by 138.9% during the third quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock worth $457,366,000 after acquiring an additional 1,267,061 shares in the last quarter. Raymond James Trust N.A. purchased a new stake in shares of Veeva Systems during the 3rd quarter worth about $231,000. Algert Global LLC lifted its holdings in shares of Veeva Systems by 64.0% during the 3rd quarter. Algert Global LLC now owns 2,254 shares of the technology company’s stock valued at $473,000 after buying an additional 880 shares during the last quarter. Centaurus Financial Inc. grew its stake in shares of Veeva Systems by 28.1% in the 3rd quarter. Centaurus Financial Inc. now owns 1,335 shares of the technology company’s stock valued at $280,000 after buying an additional 293 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in Veeva Systems in the third quarter worth approximately $49,000. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.